Indeed, in a mouse breast tumor model induced by the AT-3 cell line, which is sensitive to the PARP inhibitor olaparib, the anti-tumor effect of olaparib is blunted by an intact immune system [23]. The gene discussed is PARP1; the disease is breast neoplasm.